Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab plus modified DCF followed by hypofractionated radiotherapy in stage III squamous cell anal carcinoma
2020-006046-40Phase 2Active
- Sponsor
- CHU de Besançon
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ezabenlimab, docetaxel, cisplatin and fluorouracil in anal squamous cell carcinoma (SCCA), sponsored by CHU de Besançon. Primary endpoint: Clinical complete response rate. Started Feb 2021; status: active.
02
Drugs
ezabenlimabdocetaxelcisplatinfluorouracil
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2020-006046-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006046-40.